‘Surprisingly high’ remission rates for both ustekinumab, adalimumab in Crohn’s patients

Ustekinumab and adalimumab demonstrated equally high rates of clinical remission in biologic-naïve patients with moderate to severe Crohn’s disease through 1 year of treatment, according to results of the SEAVUE study in The Lancet.“Although SEAVUE did not demonstrate superior efficacy of ustekinumab over adalimumab, both agents showed surprisingly high rates of clinical remission at 1 year of treatment in this population of patients who were naïve to biologic agents,” Bruce E. Sands, MD, MS, chief of gastroenterology at Mount Sinai Health System and lead studyRead More

Related Articles